289 patents
Page 11 of 15
Utility
Combination Therapies Comprising Apremilast and TYK2 Inhibitors
4 Nov 20
Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject.
Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
Filed: 29 Apr 19
Utility
Heterocyclic Compounds and Their Use for Treatment of Helminthic Infections and Diseases
28 Oct 20
Natalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
Filed: 23 Apr 20
Utility
Methods for measuring small molecule affinity to cereblon
26 Oct 20
A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
Philip Paul Chamberlain, Mary Matyskiela, Godrej Khambatta
Filed: 1 Feb 18
Utility
Methods and Compositions for Reduction of Immunogenicity
21 Oct 20
Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).
Jeffrey C. Johnson, Lawrence Dearth, Haralambos Vassiliou, Jeonghoon Sun, Kandasamy Hariharan
Filed: 25 Mar 18
Utility
Methods for Treating Cancer and the Use of Biomarkers As a Predictor of Clinical Sensitivity to Therapies
21 Oct 20
Ellen FILVAROFF, Antonia LOPEZ-GIRONA, Gang LU
Filed: 2 Apr 20
Utility
Animal and Human Anti-malarial Agents
21 Oct 20
Stacie S. CANAN, Natalie Anne HAWRYLUK
Filed: 5 Jul 20
Utility
Methods of Treating Non-hodgkin Lymphoma Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
14 Oct 20
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Filed: 8 Apr 20
Utility
Isotopologues of 5-AZACYTIDINE
7 Oct 20
The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach.
John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
Filed: 26 Mar 20
Utility
Processes for the Preparation of (S)-tert-butyl 4,5-DIAMINO-5-OXOPENTANOATE
23 Sep 20
Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof.
John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
Filed: 4 Jun 20
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
21 Sep 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate.
Jerry Lee Atwood
Filed: 30 Oct 19
Utility
4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
16 Sep 20
Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
Filed: 1 Jun 20
Utility
Methods of synthesis of (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
14 Sep 20
Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Terrence Joseph Connolly, Hon-Wah Man, Periyandi Nagarajan, Chinnapillai Rajendiran, Jasti Venkateswarlu
Filed: 27 Jan 19
Utility
Methods of treating vitiligo using PD-1 binding antibodies
7 Sep 20
Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Garth E. Ringheim
Filed: 17 Sep 17
Utility
Methods Using 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE for Treatment of Intermediate Lymphocytic Lymphoma
2 Sep 20
Methods of treating, preventing or managing mantle cell lymphomas are disclosed.
Jerome B. Zeldis
Filed: 12 May 20
Utility
Methods of treating psoriasis using PD-1 binding antibodies
24 Aug 20
Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
Filed: 17 Sep 17
Utility
IDH1 Inhibitors for the Treatment of Haematological Malignancies and Solid Tumors
19 Aug 20
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
Sung Eun Choe, Bin Wu, Michael Amatangelo, Xiaolan Hu, Anjan Thakurta
Filed: 6 May 20
Utility
Crystalline 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE Monohydrate, Compositions and Methods of Use Thereof
19 Aug 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate.
Jerry Lee Atwood
Filed: 1 Mar 20
Utility
Antiproliferative Compounds and Methods of Use Thereof
12 Aug 20
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds.
Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
Filed: 26 Apr 20
Utility
CD47 Antibodies and Methods of Use Thereof
12 Aug 20
Integrin-associated protein (IAP or CD47) antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRPa) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided.
Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong
Filed: 8 May 17
Utility
PD-1 Binding Proteins and Methods of Use Thereof
12 Aug 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Brydon Bennett, Philip P. Chamberlain, Kandasamy Hariharan, Pilgrim Jackson, Marilyn Kehry, Roli Khattri, Monica Leung, Lisa Morrison, Jeonghoon Sun, Sanaa Torres, Henry H. Chan
Filed: 16 Sep 19